A direct compression process for a liposomal glutathione pharma-grade API is not a simple substitution for crystalline L-glutathione because the phospholipid lamellae surrounding the tripeptide behave as a plastic deformation layer during compaction. Spray-dried or lyophilized liposomal powders typically have low bulk density and respond to compression by particle slippage, lipid film rupture, and vesicle fusion. Published data for liposomal glutathione direct compression is limited; however, feasibility trials on rotary presses using 10 mm round concave tooling have shown that compaction force must be held below 12 kN to preserve encapsulated glutathione. At higher forces, lipid domains smear across the tablet surface, and ejection force rises because the lipid acts as a boundary lubricant only until film rupture. A starting formulation for immediate-release cores may contain 40.0% w/w liposomal glutathione powder, 28.0% w/w microcrystalline cellulose, 16.0% w/w lactose monohydrate, 8.0% w/w crospovidone, 1.0% w/w colloidal silicon dioxide, and 0.5% w/w magnesium stearate. The blend is prepared by adding the liposomal powder to the pre-mixed excipient bed and rotating at 12 rpm for 10 minutes in a bin blender; magnesium stearate is added last and mixed for 2 minutes to avoid overlubrication.

The blending area is maintained at 20–25°C and relative humidity below 40% RH. Above 50% RH, phospholipid powders absorb moisture and become tacky, causing punch-face build-up. Tablet press speed is limited to 30–50 rpm on a 10-station machine to reduce dwell-time heating. Basal ejection force is monitored; a rise above 600 N signals lipid film transfer to the die wall. If granulation is required before tableting, roller compaction with a 0.8 mm screen is preferred over high-shear wet granulation to avoid exposing the phospholipids to an aqueous binder. The tablet cores are evaluated by weight variation, hardness, and friability using USP <1216>; hardness is controlled at 40–60 N. Disintegration is performed according to USP <701> in water at 37°C ± 2°C. The operational boundary is specific to lipid-matrix powders and cannot be transferred directly to non-liposomal L-glutathione tableting.

What Moisture Threshold Separates Robust Capsule Filling From Lipid Softening?

For hard capsule filling, the limiting variable is not flowability alone but the moisture content of the powder bed relative to the capsule shell. Hydroxypropyl methylcellulose capsules are preferred over gelatin because the shell water content is 3–6% w/w, which reduces water transfer into the phospholipid layer. Gelatin capsules contain 13–16% w/w water and can induce local plasticization of the lipid film at the fill interface. A powder mixture for a size 1 capsule is composed of 45.0% w/w liposomal glutathione powder, 20.0% w/w microcrystalline cellulose, 20.0% w/w lactose monohydrate, 10.0% w/w pregelatinized starch, 1.0% w/w colloidal silicon dioxide, and 1.0% w/w sodium stearyl fumarate. The blend is passed through a 0.5 mm comill at 1,000 rpm to delump lipid agglomerates. The finished blend is held at 20–25°C and 25–35% RH for not more than 8 hours before encapsulation.

On an intermittent-motion capsule filler, tamping pin penetration is set to 12–15 mm and filling is performed at 60,000–80,000 capsules per hour for a size 1 product. Dosator machines are less suitable because the lipid powder adheres to dosator walls when the inlet air dew point exceeds 6°C. Weight variation is controlled by checking 20 capsules per station every 30 minutes against a limit of ±5.0% for average fill weight above 250 mg. If the fill moisture content exceeds 2.5% w/w, the capsule interior becomes sticky and the dissolution profile shifts because the phospholipid layer swells and releases glutathione prematurely. Pre-drying of the liposomal powder is required when the encapsulation suite cannot maintain relative humidity below 40% RH. The final capsule is tested for dissolution in 900 mL pH 1.2 at 50 rpm; for liposomal products, release is usually biphasic, with an initial free fraction followed by sustained release from intact vesicles.

Published data for a dissolution specification specific to liposomal glutathione capsules is limited. Method development therefore includes a forced-release step using a non-ionic surfactant in the dissolution medium to distinguish the free glutathione fraction from the total loaded dose. This distinction matters because a conventional immediate-release criterion applied to the free fraction alone would underestimate batch-to-batch bioavailability differences. If the capsule fill contains sodium stearyl fumarate, the dissolution medium should not be spiked with high concentrations of divalent cations, because calcium and magnesium ions bind to the phospholipid phosphate groups and alter vesicle surface charge.

Granulation of a phospholipid-bearing glutathione intermediate for dispersible oral granules requires a different endpoint logic than conventional wet massing. Water-based binders are not used because free water hydrolyzes phosphatidylcholine into lysophosphatidylcholine and free fatty acids; the degradation products change particle surface energy and cause agglomeration failure. The preferred route is top-spray fluid-bed granulation with an ethanolic binder solution of 5.0% w/w PVP K30 in ethanol, sprayed onto a pre-warmed bed of liposomal glutathione powder and mannitol in a 1:1 ratio. The binder solution is filtered through a 0.45 µm polypropylene filter before spraying. Spray rate, inlet air temperature, and product bed temperature form a narrow processing window; the product bed temperature is maintained at 28–34°C, and excursions above 38°C collapse the lipid bilayer. Inlet air dew point is kept below 4°C to prevent water condensation on the lipid granules.

The granulation endpoint is determined by sieve retention rather than torque. The target fraction is 150–500 µm, with not more than 10.0% w/w below 150 µm and not more than 5.0% w/w above 1,000 µm. After spraying, the granules are dried to a loss on drying of 1.5–2.0% w/w using 40°C inlet air and then cooled to 25°C before discharge. High-shear granulators are avoided because rotor tip speeds above 5 m/s generate local shear heating and can rupture vesicles; if a high-shear granulator is used, the impeller speed is capped at 200 rpm and the chopper is disabled after 60 seconds. The finished granules are filled into foil-lined sachets with 2.0 g silica gel desiccant. A moisture-adsorbing desiccant is required because lipid granules stored above 40% RH lose free-flowing character and clump in the sachet. Amine-containing alkalizing agents are not included in the granule formulation because a local pH rise during administration accelerates glutathione oxidation and destabilizes the lipid bilayer.

When Lyophilization Is Required for Injectable Liposomal Glutathione

When the target product is an injectable liposomal glutathione, the manufacturing sequence shifts from dry powder mixing to aqueous lipid processing and aseptic lyophilization. The process begins with the hydration of a phospholipid-cholesterol film using a nitrogen-sparged glutathione solution in water for injection. The lipid phase commonly contains hydrogenated phosphatidylcholine and cholesterol in a 55:45 molar ratio; the aqueous phase contains reduced glutathione at 10–50 mg/mL and trehalose or sucrose at 5–10% w/v as a cryoprotectant. The coarse dispersion is reduced in size by high-shear homogenization at 10,000–15,000 rpm for 30–60 minutes, then processed through a high-pressure homogenizer at 10,000–20,000 psi for 3–5 passes. The target mean particle diameter is 80–120 nm, with a polydispersity index below 0.2 by dynamic light scattering per ISO 22412:2017. After homogenization, the dispersion is extruded through 80 nm polycarbonate track-etched membranes to narrow the size distribution. The extruded dispersion is dialyzed or diafiltered to remove unencapsulated glutathione if high entrapment efficiency is required.

Sterile filtration is possible only when the liposome size remains below 200 nm; a 0.22 µm polyethersulfone filter is used with a prefilter in line, and filter integrity is verified by bubble point per ASTM F838-20. The filtered dispersion is filled into depyrogenated vials and lyophilized. An indicative lyophilization cycle freezes the vial contents to -45°C at 0.5°C/min, holds for 2 hours, then performs primary drying at -30°C and 0.1 mbar for 18–24 hours, followed by secondary drying at 20°C for 6–8 hours. These parameters are adjusted based on fill depth and freeze-dryer shelf mapping. The final cake is tested for residual moisture by Karl Fischer coulometry; a limit of not more than 2.0% w/w is applied because water above this level increases phospholipid hydrolysis and glutathione dimerization during storage. Reconstitution time should be less than 2 minutes with swirl; the reconstituted liposomes are expected to retain a mean diameter below 150 nm and encapsulation efficiency above 90% as measured by minicolumn centrifugation or ultrafiltration.

Liposomal injectables are not terminally sterilized because saturated steam at 121°C for 15 minutes degrades glutathione and promotes phospholipid hydrolysis; gamma irradiation generates free radicals that oxidize the thiol group and crosslink unsaturated lipids. Aseptic processing under EU GMP Annex 1 is therefore mandatory. Environmental monitoring includes settle plates, contact plates, and active air sampling during filling. The sterility test is performed according to USP <71>; endotoxin is measured by limulus amebocyte lysate per USP <85>. Subvisible particulate matter is controlled by USP <788>. The in-process sampling plan follows 21 CFR 211.110 because the product is not a simple solution and the blending of the lipid and aqueous phases is a critical step.

Extemporaneous Oral Liquid Conversion in Hospital Pharmacies

A hospital pharmacy converting liposomal glutathione powder into an oral liquid should not use a standard oral vehicle with a neutral pH unless the preparation is used immediately. Reduced glutathione in water undergoes thiol-disulfide exchange and metal-catalyzed oxidation more rapidly above pH 6.0; therefore, a 0.05 M citrate buffer at pH 4.5–5.0 is used as the diluent. The compounding procedure calls for 1.0 g of liposomal glutathione powder to be suspended in 50 mL of citrate buffer containing 0.01% w/v disodium edetate as a chelator for trace divalent cations. The suspension is mixed by gentle inversion, not vortexed, to avoid rupturing the liposomes. It is stored in an amber glass bottle at 2–8°C and used within 24 hours if no preservative is present. Published stability data for this specific liposomal glutathione oral liquid is limited, so the hospital pharmacist should validate the beyond-use date by a stability-indicating assay.

The oral liquid is intended for immediate administration after shaking. The liposomal component may delay release of glutathione in the stomach, but the free fraction in the diluent is available immediately. If the formulation contains acidic buffer, coadministration with aluminum or magnesium trisilicate antacids should be avoided. The pH after reconstitution is confirmed with a calibrated pH meter at 25°C; the limit is 4.5–5.0. Osmolarity is not critical for oral administration, but repeated doses should be prepared fresh. If a sweetener is required, sorbitol at 20% w/v may be added after the liposomal powder is wetted; high osmotic pressure can draw water from the liposomal core and should be minimized. Any residual undissolved material should be reported to the pharmacist as a possible sign of vesicle aggregation rather than simple insolubility.

For a sterile injectable presentation that must remain liquid rather than lyophilized, the process window is narrower because the liposomal dispersion must retain its particle size distribution in aqueous suspension until administration. The formulation is filled into nitrogen-flushed vials or pre-filled syringes with a headspace oxygen content below 0.2% v/v. The aqueous phase is buffered at pH 5.5–6.5 with histidine or citrate; the choice of buffer affects both glutathione stability and phospholipid hydrolysis. The fill volume is 1–5 mL, and the liposome concentration is adjusted to deliver 25–50 mg elemental glutathione per mL. The product is stored at 2–8°C and must not be frozen, because freeze-thaw cycles cause vesicle fusion, drug leakage, and subvisible particulates.

In-process checks include pH, osmolality, particle size by dynamic light scattering per ISO 22412:2017, and encapsulation efficiency. A subvisible particle count by USP <788> is performed at release and after 24 hours at room temperature if the vial is used for infusion. The liquid presentation is not autoclaved; aseptic processing is required because the liposomes and the peptide degrade under terminal sterilization. Filter compatibility is tested with the actual formulation because liposomal dispersions can plug membranes even when the mean size is below 200 nm. The maximum filtration volume per unit filter area is established by a filterability test using differential pressure logging across a 0.22 µm sterilizing-grade filter.

Nitrogen sparging is maintained during bulk preparation because dissolved oxygen accelerates oxidation of the thiol group. A dissolved oxygen probe is used to confirm oxygen below 0.1 mg/L in the bulk solution before filling. The vials are stoppered under vacuum or nitrogen overlay; residual oxygen in the headspace is measured by a non-destructive laser-based headspace analyzer. If the oxygen content rises above 0.5% v/v during stability, the batch is not considered acceptable for release because the lipid bilayer becomes more permeable to glutathione leakage.

Tablet Cores Containing Liposomal Glutathione Should Not Enter Standard Aqueous Film Coating Without Prior Seal Coating

Aqueous film coating of a liposomal glutathione tablet introduces a process conflict because the lipid layer softens at the tablet surface when the bed temperature exceeds 35–40°C, and water droplets from the coating dispersion can create pits. A seal coat of 3.0–5.0% w/w HPMC 5 cps is applied first at a pan speed of 6–10 rpm, inlet air temperature of 50–60°C, and bed temperature of 30–35°C. The spray rate is kept at 5–10 g/min for a 500 g batch in a 2 kg coating pan. After the seal coat dries, an enteric coating may be applied if gastric acid degradation of non-liposomal glutathione is a concern, but the enteric polymer must be applied below 35°C with a plasticizer level of 10–20% w/w based on polymer solids.

Tablets are preheated for 5 minutes before spraying and cooled to 25°C before unloading. Film coating under higher temperature leads to edge wear and visible lipid bleed, requiring batch rejection. The coating pan itself should be conditioned to 35–45% RH; lower humidity is acceptable, but higher humidity causes premature swelling of the HPMC seal coat. Enteric polymers that require a neutralization step with ammonia solution should be avoided because residual amine can create local alkaline conditions in the tablet core and destabilize the phospholipid bilayer. The coated tablets are tested for disintegration according to USP <701> with a simulated gastric fluid acid stage followed by pH 6.8 buffer if an enteric coating is applied.